Diagnostic accuracy of contrast-enhanced diffusion-weighted MRI for liver metastases of pancreatic cancer: towards adequate staging and follow-up of pancreatic cancer - DIA-PANC study: study protocol for an international, multicenter, diagnostic trial

G Litjens, D M Rivière, E J M van Geenen, S A Radema, L A A Brosens, M Prokop, C J H M van Laarhoven, J J Hermans, G Litjens, D M Rivière, E J M van Geenen, S A Radema, L A A Brosens, M Prokop, C J H M van Laarhoven, J J Hermans

Abstract

Background: At the time of surgery, approximately 10-20% of the patients with pancreatic cancer are considered unresectable because of unexpected liver metastasis, peritoneal carcinomatosis or locally advanced disease. This leads to futile surgical treatment with all the associated morbidity, mortality and costs. More than 50% of all liver metastases develop in the first six months postoperatively. These (subcentimeter) liver metastases are most likely already present at the time of diagnosis and have not been identified pre-operatively, due to the poor sensitivity of routine preoperative contrast-enhanced CT (CECT).

Methods: The DIA-PANC study is a prospective, international, multicenter, diagnostic cohort study investigating diffusion-weighted, contrast-enhanced MRI for the detection of liver metastases in patients with all stages of pancreatic cancer. Indeterminate or malignant liver lesions on MRI will be further investigated histopathologically. For patients with suspected liver lesions without histopathological proof, follow up imaging with paired CT and MRI at 3-, 6- and 12-months will serve as an alternative reference standard.

Discussion: The DIA-PANC trial is expected to report high-level evidence of the diagnostic accuracy of MRI for the detection of liver metastases, resulting in significant value for clinical decision making, guideline development and improved stratification for treatment strategies and future trials. Furthermore, DIA-PANC will contribute to our knowledge of liver metastases regarding incidence, imaging characteristics, their number and extent, and their change in time with or without treatment. It will enhance the worldwide implementation of MRI and consequently improve personalized treatment of patients with suspected pancreatic ductal adenocarcinoma.

Trial registration: ClinicalTrials.gov Identifier: NCT03469726 . Registered on March 19th 2018 - Retrospectively registered.

Keywords: Liver metastases; MRI; Pancreatic cancer; Staging.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of study schedule and procedures

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
    1. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol. 2005;23(20):4538–4544.
    1. Raman SP, Reddy S, Weiss MJ, Manos LL, Cameron JL, Zheng L, et al. Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol. 2015;204(1):W37–W42.
    1. Glant JA, Waters JA, House MG. Zyromski NJ, Nakeeb A, Pitt HA, et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150(4):607–616.
    1. Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016;7:CD009323.
    1. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European J Surg Oncol. 2009;35(6):600–604.
    1. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1–2):362–375.
    1. Holzapfel K, Reiser-Erkan C, Fingerle AA, Erkan M, Eiber MJ, Rummeny EJ, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging. 2011;36(2):179–184.
    1. Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol. 2001;38(2):105–112.
    1. Paik KY, Choi SH, Heo JS, Choi DW. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma. World J Gastrointestinal Oncol. 2012;4(5):109–114.
    1. Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology. 2011;260(2):446–453.
    1. Schima W, Ba-Ssalamah A, Kolblinger C, Kulinna-Cosentini C, Puespoek A, Gotzinger P. Pancreatic adenocarcinoma. Eur Radiol. 2007;17(3):638–649.
    1. Danet IM, Semelka RC, Nagase LL, Woosely JT, Leonardou P, Armao D. Liver metastases from pancreatic adenocarcinoma: MR imaging characteristics. J Magnetic Resonance Imaging. 2003;18(2):181–188.
    1. Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical Management of Patients with Unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, Single Institution Experience. J Gastrointest Surg. 2011;15(11):1917–27.
    1. Eiber M, Fingerle AA, Brugel M, Gaa J, Rummeny EJ, Holzapfel K. Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol. 2012;81(4):683–691.
    1. Lowenthal D, Zeile M, Lim WY, Wybranski C, Fischbach F, Wieners G, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol. 2011;21(4):832–840.
    1. Holzapfel K, Bruegel M, Eiber M, Ganter C, Schuster T, Heinrich P, et al. Characterization of small (</=10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. Eur J Radiol. 2010;76(1):89–95.
    1. Galea N, Cantisani V, Taouli B. Liver lesion detection and characterization: role of diffusion-weighted imaging. J Magnetic Resonance Imaging. 2013;37(6):1260–1276.
    1. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. National Comprehensive Cancer Network. NCCN Guideline:Pancreatic Adenocarcinoma. Version 1.2020. . Accessed 20 Mar 2020.
    1. National Institute for Health and Care Excellence. NICE Guideline: Pancreatic cancer: diagnosis and management in adults. CG32. 2018. . Accessed 20 Mar 2020.
    1. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–v68.
    1. Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082–2088.
    1. Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K, et al. Clinical practice guidelines for pancreatic Cancer 2016 from the Japan pancreas society: a synopsis. Pancreas. 2017;46(5):595–604.
    1. Riviere DM, van Geenen EJM, van der Kolk BM, Nagtegaal ID, Radema SA, van Laarhoven C, et al. Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI. Abdominal radiology. 2019;44(5):1756–1765.
    1. Marion-Audibert AM, Vullierme MP, Ronot M, Mabrut JY, Sauvanet A, Zins M, et al. Routine MRI with DWI sequences to detect liver metastases in patients with potentially Resectable pancreatic ductal carcinoma and Normal liver CT: a prospective multicenter study. AJR Am J Roentgenol. 2018;211(5):W217–WW25.
    1. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207.
    1. Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, et al. Multi-institutional validation study of the American joint commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265(1):185–191.
    1. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. Am J Roentgenol. 2011;196(2):W138–WW43.
    1. Jones SR, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J. 2003;20(5):453–458.
    1. Riviere DM, van Geenen EJM, van der Kolk BM, Nagtegaal ID, Radema SA, van Laarhoven CJHM, et al. Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI. Abdom Radiol (NY). 2019;44(5):1756–65.
    1. Wei C, Tan J, Xu L, Juan L, Zhang SW, Wang L, et al. Differential diagnosis between hepatic metastases and benign focal lesions using DWI with parallel acquisition technique: a meta-analysis. Tumour Biol. 2015;36(2):983–990.
    1. Kele PG. Diffusion weighted imaging in the liver. World J Gastroenterol. 2010;16(13):1567.
    1. Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M. Magnetic resonance imaging of liver metastasis. Semin Ultrasound CT MR. 2016;37(6):533–548.
    1. Kim HJ, Lee SS, Byun JH, Kim JC, Yu CS, Park SH, et al. Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology. 2015;274(3):712–722.
    1. van der Geest LGM, Lemmens V, de Hingh I, van Laarhoven C, Bollen TL, Nio CY, et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017;104(11):1568–1577.
    1. Hong SB, Choi SH, Kim KW, Kim SY, Kim JH, Kim S, et al. Meta-analysis of MRI for the diagnosis of liver metastasis in patients with pancreatic adenocarcinoma. J Magnetic Resonance Imaging. JMRI. 2019;29(7):3553–63.
    1. Alabousi M, MD MI, Salameh JP, Satkunasingham J, Kagoma YK, Ruo L, et al. MRI vs. CT for the Detection of Liver Metastases in Patients With Pancreatic Carcinoma: A Comparative Diagnostic Test Accuracy Systematic Review and Meta-Analysis. J Magnetic Resonance Imaging. JMRI. 2020. 10.1002/jmri.27056. Online ahead of print.
    1. Boll DT, Merkle EM. Imaging at higher magnetic fields: 3 T versus 1.5 T. Magn Reson Imaging Clin N Am. 2010;18(3):549–64 xi-xii.
    1. Soher BJ, Dale BM, Merkle EM. A review of MR physics: 3T versus 1.5T. Magn Reson Imaging Clin N Am. 2007;15(3):277–290.
    1. Donati OF. Chong D, Nanz D, Boss A, Froehlich JM, Andres E, et al. Diffusion-weighted MR imaging of upper abdominal organs: field strength and Intervendor variability of apparent diffusion coefficients. Radiology. 2014;270(2):454–463.
    1. Use of Diffusion-weighted MRI for the Detection of Liver Metastases in Potentially Resectable Pancreatic Adenocarcinomas: a Prospective Multicenter Study. World Health Organization Trial Registry. 2016. Available at: TrialID=NCT02896946. Accessed on 19 Feb 2020.
    1. Evans J. Evaluation of multi-parametric magnetic resonance imaging for characterising lymph node status, peritoneal and liver metastasis in pancreatic cancer. World Health Organization Trial Registry. 2017. Available at: TrialID=ISRCTN15395684. Accessed on 19 Feb 2020.
    1. Bagia JS. Patients with locally resectable pancreatic cancer randomized to standard preoperative assessment or additional primovist MRI to further evaluate for liver metastases comparing 12 month recurrence rate between the 2 groups World Health Organization Trial Registry. 2019. Available at: TrialID=ACTRN12614001287628. Accessed on 19 Feb 2020.
    1. Jiangfa L. The comparative study for dd-eob-dtpa enhanced magnetic resonance imaging and enhanced CT in hepatic metastasis of pancreatic cancer. World Health Organization Trial Registry. 2019. Available at: TrialID=ChiCTR1900022842. Accessed on 19 Feb 2020.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する